Adam Feuerstein
Verified
As seen in:
STAT,
Forbes,
Business Insider,
Fox News,
Scribd,
CNBC,
MIT News,
PBS NewsHour,
Boston.com,
Scientific American,
Flipboard
and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Adam Feuerstein
Roche gets a lung cancer win with its KRAS drug divarasib
Adobe Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54. Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71.
Gilead’s IBD drug eliminated symptoms for patients, mid-stage study finds
Justin Sullivan/Getty Images Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and biotechnology. Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology.
On Wall Street, there’s trouble stirring for biotech
Adam Feuerstein/STAT Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54. This story first appeared in Adam’s Biotech Scorecard, a STAT newsletter. Sign up here to get it delivered to your inbox.
FDA approves Protagonist and Takeda’s drug for rare blood cancer
Adobe Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54. The Food and Drug Administration on Friday approved a new treatment for a rare and slow-growing cancer that causes an overproduction of red blood cells.
One of Rhode Island’s most-wanted fugitives appears to have been secretly working as a biotech executive
MetroWeatherPoliticsSportsBusinessPuzzlesRhode IslandGlobe MagazineOpinionHealth careArtsLifestyleEducationCambridge & SomervilleMoney, Power, InequalitySpotlightTechnologyClimateCarsReal EstateEvents This story is republished from STAT, the health and medicine news site that’s a partner to the Globe. Sign up for STAT’s free Morning Rounds newsletter here.
A most-wanted fugitive appears to have been secretly working as a biotech executive
Culture Now A Mysterious Woman’s Name Was Etched Into Stone Nearly 2,000 Years Ago. Archaeologists May Have Finally Found Her Identity. Popular Mechanics - Tim Newcomb • 14m The inscription itself offers little information about the woman, but she must have been a prominent member of society. Here’s what you’ll learn when you read this story: A second-century well in Roman Butrint features a distinct inscription mentioning the mysterious Junia Rufina. • The inscription …
931 days. The drug approval scandal hiding in plain sight
Metals 3 hours ago World-First 'Super Alloy' Could Transform The Way Metals Are Made ScienceAlert - David Nield • 3h Metal alloys are used everywhere from aircraft to cutlery, making them an indispensable part of modern life.
Halfway into the year, biotech is booming
Plus: What to expect at the FDA’s Capricor advisory panel meeting Mark Lennihan/AP By Adam Feuerstein July 2, 2026 Senior Writer, Biotech Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.
‘Synthetic lethality’ could trigger another round of biotech M&A
Enthusiasm about the approach to cancer treatment could trigger some creative deal-making This image shows pancreatic cancer cells (nuclei in blue) growing as a sphere encased in membranes.National Cancer Institute/USC Norris Comprehensive Cancer Center By Adam Feuerstein June 11, 2026 Senior Writer, Biotech Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology.
At ASCO, talk of barriers to cancer care, new treatments, and other big takeaways
At ASCO, talk of barriers to cancer care, new treatments, and other big takeaways Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. …
A standing ovation for RevMed, and caution for Akeso
Security 11 hours ago Random Standard Wi-Fi Routers Can Scan Your Body to Identify Exactly Who You Are, Alarming New Research Finds futurism.com - Joe Wilkins • 11h "With this hardware making its way into millions of homes, the privacy concerns are severe." If you were paranoid about digital tracking before, you … Social Sciences 1 day ago The Trump Administration Is Done With Social Science The Atlantic - By Hana Kiros • 1d The National Science Foundation division that covers social,...
Biotech veteran Jeremey Levin on why the industry's future is secure, but American leadership is at risk
Biotech veteran Jeremey Levin on why the industry's future is secure, but American leadership is at risk Biotech is producing scientific breakthroughs that once seemed impossible. But according to longtime industry executive Jeremy Levin, the …
FDA rejects Regenxbio’s rare-disease gene therapy
1 day ago Deep tech startups in sectors such as space, semiconductors, and biotech take far longer to mature than conventional ventures. Because of that India is adjusting its startup rules, and mobilizing public capital, hoping to help more of them make it to commercial products. This week, the Indian …
Insmed basks in the success of its lung disease drug — and prepares for what’s next | Flipboard
7 hours ago The disease affects as many as 80 million in the U.S. alone. Now Apnimed, the $400 million company behind the first ever pill to treat it, is preparing to file for FDA approval. In November 2016, Harvard researcher Dr. Luigi Taranto Montemurro was in a lab at Brigham and Women’s Hospital observing …
J&J's two-drug combo blocked tumors in advanced multiple myeloma
Arcellx Inc. (NASDAQ:ACLX) shared new data on Saturday from its pivotal Phase 2 iMMagine-1 study of anitocabtagene autoleucel (anito-cel) for …
Startups push the FDA and biotech booms in North Carolina
Emma Stone and Jesse Plemons make the case for the wild ride that is 'Bugonia' Jesse Plemons has a plea: Pause Netflix and go see “Bugonia” in the theater. The film, in which he plays a conspiracy theorist who kidnaps and …
Trump, Chinese biotech, and an industry career reshaped by illness
Trump, Chinese biotech, and an industry career reshaped by illness Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. …
Viking's obesity flop, 'pharma to table' drug sales
Dorsey Hernandez turned to the duodenal switch weight-loss surgery after obesity took a toll on her health. Doctor describes how it works and who is a good candidate. After years of overeating and yo-yo dieting, Dorsey Hernandez’s health began to suffer. Standing 5 feet, 5 inches tall, she weighed …
Why Sarepta may not survive its current gene therapy crisis
Stubborn, overlooked regions of the human genome decoded at last It’s been more than 2 decades since the human genome was mapped for the first time. This achievement, while tremendous at the time, was based on the …
FDA to request Sarepta Therapeutics halt shipments of Duchenne gene therapy
Sarepta plunges after third patient death tied to gene therapy - report (SRPT:NASDAQ) Sarepta Therapeutics (NASDAQ:SRPT) said a third patient has died from acute liver failure after receiving one of its gene therapies, intensifying …
The year is half over. Here’s where the biotech industry stands
23 hours ago Microsoft mass layoffs: Thousands of jobs cut, Xbox division hit hard A bad day for Microsoft. Microsoft is planning to cut thousands of jobs, its biggest round of layoffs in years. The company confirmed it is going to layoff around 9,000 people — about 4 percent of its workforce — on Wednesday, according to a report from The Seattle Times.
Disagreements over Duchenne therapy, management style may have led to ouster of key FDA official
1 hour ago I found the easiest way to delete myself from the internet (and you shouldn't wait to use it, too) If you're looking for a data removal service that can remove you from data broker sales lists and people search websites, Incogni should be on your … 5 hours ago Your Apple Watch Is About to Get a Pretty Cool New Ability Apple is gearing up to give your Apple Watch some of your iPhone’s standout features.
At ASCO Day 3, AstraZeneca dominates, Takeda reveals experimental drug data, Eli Lilly serves salad
In the wake of the recent sweeping federal cuts to the US Agency for International Development (USAID) and the US President’s Emergency Plan for AIDS …
Biotech investor activism is on the rise
5 hours ago What warped the minds of serial killers? Lead pollution, a new book argues. Ted Bundy, the Green River Killer, and others terrorized the Pacific Northwest. "Murderland" asks what role polluters played. When Ted Bundy was a … Now A Skull Washed Up on a Beach 30 Years Ago. Students Just ID’ed the Remains. The mystery man died during a storm alongside his crew in 1844.
Vinay Prasad is outraged, and now at the FDA. How will biotech deal?
13 hours ago The Old Man and the AOC. The Gaza Famine Myth. Plus. . . It’s Wednesday, May 7. This is The Front Page, your daily window into the world of The Free Press—and our take on the world at large. Today: Does … 1 day ago FDA names oncologist Dr. Vinay Prasad, a Covid vaccine critic, as the new vaccine chief Prasad was an outspoken critic of the FDA’s response to the pandemic, including the former vaccine chief, Dr. Peter Marks.
Vertex reports an earnings miss and pause on cystic fibrosis trial
1 day ago Nutrionist says 'best food for fatty liver' is common hot drink — not green tea A nutritonist has revealed the "best food for a fatty liver" and it's a common hot drink.
Immunovant replaces CEO, makes other changes as Roivant tightens control
2 hours ago Pope Francis has died, the Vatican announced on Monday—after months of severe health ailments, including a bout of severe pneumonia—ending a more than decade-long reign during which the Roman Catholic Church witnessed several key shifts. Key Facts Francis’ death was announced by Cardinal Kevin …
Vaccine critic’s apparent selection to head HHS autism study shocks experts
News that a major player in the anti-vaccine community may have been tasked by the Department of Health and Human Services to conduct a study looking for a link between immunizations and autism has been met with incredulity and dropped jaws among vaccine experts and others familiar with the anti-vaccine movement.
RFK Jr. is wrong in saying vaccines cause autism. Here's the science
Vaccines do not cause autism. You’ve almost certainly read that before — probably hundreds of times. But many people do not believe it, perhaps because too often it is repeated without a real explanation of how we know that. So here is an attempt to offer that explanation. Of course, the issue is in the news again because Robert F.
Feds accuse Walgreens of filling 'millions' of illegal opioid prescriptions
After several years of investigation, the U.S. Department of Justice filed a civil lawsuit accusing Walgreens of illegally dispensing millions of prescriptions for opioid painkillers and failing to fulfill its role as a critical gatekeeper in the nation’s health care system. The lawsuit is only the latest to blame one of the largest pharmacy chains in the U.S. for contributing to a long-running opioid crisis that has led to the death of hundreds of thousands of Americans.
Sanofi advances a drug for a rare, platelet-destroying disease
When Grilling Steaks, Follow The 3-3-2-2 Rule For Perfect Results Grilling perfect steak is all about timing, and we don't mean the total time you cook it for the perfect temp. One simple rule will make all the …
Crypto for CRISPR, a new RNAi startup, & a Nobel for AI
7 hours ago Needles and tubes no longer faze Puttinant Rungsunlohakul, nor do bags of deep red blood. For most of his life, the 35-year-old has travelled to hospital every three or four weeks, where these tools deliver critical transfusions that prevent his body from shutting down. “If you don’t get [the …
STAT+: Pharmalittle: UCB Selling A Chinese Business, Tome Layoffs, And More - STAT
Belgian drugmaker UCB is selling its Chinese neurology and allergy business for $680 million. Happy Monday, Pharmalittle family. Adam Feuerstein here, once again filling in for Ed. I have been assured that Ed is staying caffeinated, even in his
STAT+: Pharmalittle: We’re Reading About A Negative U.K. Review Of Leqembi, Bavarian Nordic’s Strong Earnings, And More - STAT
STAT+: Pharmalittle: We’re reading about a negative U.K. review of Leqembi, Bavarian Nordic’s strong earnings, and more U.K. cost-effectiveness watchdog issued draft guidance saying Leqembi’s limited benefits for Alzheimer's patients do not justify its costs. Good morning, Pharmalittle fans! Adam Feuerstein here, filling in for Ed. I drink my morning coffee from a heavy, thick diner mug. I suggest you
PDS Biotech Aligns With FDA On Phase 3 Trial In HPV16-Positive First-Line Recurrent Or Metastatic Head And Neck Cancer
Company to initiate Phase 3 VERSATILE-003 trial in Q4 2024 Conference Call Today at 8:00 a.m. Eastern Time PRINCETON, N.J., Aug.
With resignations of top leaders, Cassava Sciences exposes a dark, ugly corner of the Alzheimer’s disease world
8 hours ago They reveal unusual — and not-so-talked-about — places skin cancer can show up, plus surprising signs of the disease. When board-certified dermatologist Dr. Elizabeth Tanzi was pregnant with her first child, a dark spot formed on her lower leg. Six months later, when the spot began to grow, the …
B. Riley Securities Maintains Buy on PDS Biotechnology, Lowers Price Target to $9
Benzinga News, Price Target, Analyst Ratings PDSB B. Riley Securities analyst Kalpit Patel maintains PDS Biotechnology (NASDAQ:PDSB) with a Buy and lowers the price target from $11 to $9.
PDS Biotech Shares Data Update From Ongoing VERSATILE-002 Phase 2 Clinical Trial In Head and Neck Cancer
Majority of patients continue to be followed for survival with multiple patients approaching 3 years Median Overall Survival (mOS) remains at 30 months based on the most recent data cut with approximately six months of additional follow-up PRINCETON, N.J., June 12, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development...
Merus drug, with immunotherapy, boosts tumor response in patients with head and neck cancer
Boy given 'devastating' diagnosis after going to hospital with a twinge in his knee His bravery in the face of horrendous adversity has been so inspiring it has crossed the divide of United and City fans. Jake Last was showing real …
STAT+: Pharmalittle: We’re Watching More Positive Data For Ozempic, A Lilly Factory Expansion, And More - STAT
It’s an honor to fill in for Ed Silverman this morning. There is only one Pharmalot, but when he’s out, his fellow STAT coffee and tea drinkers
Live! From the STAT Breakthrough Summit West
Capital Markets 4 hours ago MorphoSys gains after Novartis discloses all tender offer conditions were met Seeking Alpha - Joshua Fineman • 4h MorphoSys AG (NASDAQ:MOR) rose 4.6% after Novartis (NYSE:NVS) said all tender offer conditions for its EUR 68 per share deal were met.
'PDS Biotech's Survival Benefit Is Absurdly Overstated' - By Adam Feuerstein/ STAT News
https://www.statnews.com/2024/05/16/pds-biotech-survival-benefit/ This is the online edition of Adam's Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered every Thursday to their inbox. Hello, friends! I'm in San Francisco for the STAT Breakthrough Summit. Later today, I'll be "fireside chatting" with Cytokinetics CEO Robert Blum. It's not too late to join us virtually. Check out details here.
PDS Biotechnology Q1 2024 GAAP EPS $(0.30) Beats $(0.37) Estimate, Cash $66.6M
Benzinga Earnings, Earnings Beats, News PDSB PDS Biotechnology (NASDAQ:PDSB) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.37) by 18.92 percent. This is a 6.25 percent increase over losses of $(0.32) per share from the same period last year.
STAT+: Annovis Bio Delivers Candor On Its Parkinson’s Study, Even If It Doesn’t Inspire Much Confidence - STAT
STAT+: Annovis Bio delivers candor on its Parkinson’s study, even if it doesn’t inspire much confidence Annovis Bio delivers candor on its Parkinson’s study, even if it doesn’t inspire much confidence. Annovis Bio had my biotech bull%^&! meter running red after it made a late change to the design of a Phase
Mixed results on therapy for muscular dystrophy
BODY Sarepta Therapeutics said Monday that its gene therapy for Duchenne muscular dystrophy failed to improve muscle function compared to a placebo in a large clinical trial — likely a major disappointment for patients and doctors who have been desperately awaiting the treatment for years. The company said all patients in the study improved and that secondary measurements indicated the drug was having an effect.
STAT+: It’s Time For The FDA To Halt Cassava Sciences’ Alzheimer’s Clinical Trials - STAT
STAT+: It’s time for the FDA to halt Cassava Sciences’ Alzheimer’s clinical trials Patient safety is paramount to the FDA, so stopping Cassava’s two Phase 3 studies is the ethically correct thing to do, @adamfeuerstein writes. The Food and Drug Administration should halt Cassava Sciences’ ongoing clinical trials in Alzheimer’s disease. That, and other thoughts on the
STAT+: Pharmalittle: Novartis R&D Hub’s Name Change Reflects Strategy Shift; Lilly’s Mounjaro Backed By U.K. Watchdog - STAT
Save for Later Save STAT+ For Later Good morning, Pharmalittle family! Adam Feuerstein here, filling in for Ed. My morning coffee was brewed with Peru Cajamarca beans, sourced by Equator and lightly roasted
STAT+: Health Care CEOs Hauled In $4 Billion Last Year As Inflation Pinched Workers, Analysis Shows - STAT
The health care industry didn’t just provide a safe haven for jittery stock investors in 2022, a year defined by inflation and higher interest rates. It also provided a stable stream of wealth for top executives, who collectively pocketed billions of dollars in what was otherwise a rough patch for the economy. By almost every measure, 2022 for the stock market. But health care stocks than other companies as the amount of care received and prescriptions filled returned closer to pre-pandemic norms.
STAT+: The Biotech Scorecard For The Third Quarter: 15 Stock-moving Events To Watch - STAT
Save for Later Save STAT+ For Later Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third quarter:
STAT+: Biotech Executive Nominated To Biogen Board Is Mother Of Director’s Child, Records Show - STAT
Save for Later Save STAT+ For Later Biotech executive nominated to Biogen board is mother of director's child, records show. Biogen, a biotech giant plagued by years of boardroom strife, said late Monday that the longtime and polarizing director Alex Denner
Show More
loading
Actions
Get in touch with Adam
Contact Adam, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack